This study aims to evaluate the efficacy and safety of 177Lu-PSMA-617 as a systemic therapy in patients with PSMA-positive advanced clear cell renal cell carcinoma (ccRCC).
The name of the study drug involved in this research study is:
-177Lu-PSMA-617 (a type of radioligand therapy)

Start Date01 Nov 2025

Sponsor / Collaborator

Dana-Farber Cancer Institute, Inc.

[+1]

NCT06783348

/ Not yet recruitingPhase 2IIT

Phase II Trial Evaluating the Efficacy of 177Lutetium-PSMA-617 Treatment in Patients With Metastatic Clear Cell Renal Carcinoma Cell With Progressive Disease on First-line or Second-line Systemic Treatment

Background This study is for adults with advanced kidney cancer that has spread to other parts of the body and has continued to progress despite treatment with immunotherapy and targeted therapy. Unfortunately, treatment options at this stage of the disease are limited. The existing treatments' ability to work against cancer has not been fully looked into.
Rationale The goal of this study is to examine if a new drug treatment called 177Lutetium-PSMA-617, hereafter referred as 177Lu-PSMA-617, which holds the active ingredient 177Lutetium-PSMA and has been used as a standard treatment for advanced prostate cancer since December 2022, can also help treat advanced kidney cancer.
The drug 177Lu-PSMA-617 is being tested as an experimental treatment that targets a specific protein on cancer cells. This protein, known as prostate-specific membrane antigen (PSMA), is present on the surface of kidney cancer cells. Therefore, before the treatment begins, participants will undergo a PET (positron-emission tomography) scan to check if their kidney cancer cells express high levels of PSMA. This scan uses a small amount of radioactive material (in the form of 177Lutetium) to visualize the presence of PSMA on the cancer cells. Only participants who test positive for PSMA can take part in the study. In this approach, PSMA serves two purposes. First, it helps assess whether the cancer expresses this protein and allows 177Lu-PSMA-617 to specifically target and attach to the cancer cells. Second, 177Lu-PSMA-617 delivers a small amount of radiation directly to the tumour, which helps kill cancer cells while minimizing damage to normal cells. This type of treatment is known as a radiopharmaceutical.
Objective The primary aims are to find out if 177Lu-PSMA-617 is useful against kidney cancer and to assess its safety. Throughout the study, participants will undergo several imaging assessments to check their disease and response to treatment.
The study also includes the collection of tissue samples. Together with the information collected from the imaging assessments, this will allow further research into markers that may lead to earlier detection of tumour spread or help identify individuals who may benefit more from treatment with 177Lu-PSMA-617.
Treatment All participants will receive 177Lu-PSMA-617 through an intravenous injection at a standard dose of 7,400 MBq (megabecquerel: a measure of radioactivity). Treatments will be administered approximately every six weeks, for a maximum of six times.
Blood tests are done before and during treatment to check the participant's health and to detect any early side effects from the treatment. Different types of scans are performed before, during, and after 177Lu-PSMA-617 administration to check how well the treatment is working. After treatment ends, follow-up visits will be scheduled every six weeks during the first year. In the second year, your doctor will decide how often you need to come in for visits. These appointments are important for monitoring how the body continues to respond to the treatment. The entire study period will last approximately two years from the time of study entry.
Participants
The study will include approximately 56 participants who will be tested for PSMA expression, to obtain a minimum of 48 participants expressing PSMA entering the study. To qualify, participants must:
* Be diagnosed with advanced kidney cancer previously treated with immunotherapy and targeted therapy.
* Test positive for PSMA on a PET scan.
* Be generally healthy and able to perform daily activities.
* Be at least 18 years of age.
Benefit-risk analysis The drug 177Lu-PSMA-617 has proven to work well in treating advanced prostate cancer and could be a promising new treatment possibility for kidney cancer, although this has not yet been shown. By joining this study, participants will contribute to valuable research to better understand kidney cancer and improve treatment options for future patients. Participating in this study offers a chance to try a new treatment, which might help people with advanced kidney cancer live longer and prevent the disease from getting worse, especially for those who have limited treatment options left after immunotherapy and targeted therapy.
With all new treatments, there are possible risks and side effects associated with them. Side effects of the drug 177Lu-PSMA-617 may include feeling tired, nausea, dry mouth, loss of appetite, and changes in blood cells. While not all side effects are known yet, the study team will carefully follow participants for any side effects during and after treatment. It is important to understand that while the study is being done to provide new information, there are still some questions on the treatment's safety and how well it will work.

Start Date30 Oct 2025

Sponsor / Collaborator-

100 Clinical Results associated with Lutetium (177 Lu) Vipivotide Tetraxetan

100 Translational Medicine associated with Lutetium (177 Lu) Vipivotide Tetraxetan

100 Patents (Medical) associated with Lutetium (177 Lu) Vipivotide Tetraxetan

628

Literatures (Medical) associated with Lutetium (177 Lu) Vipivotide Tetraxetan

15 Oct 2025·EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

PSMA targeted Therapy: From molecular mechanisms to clinical breakthroughs in castration-resistant prostate cancer.

Review

Author: Wu, Denglong ; Wang, Xin'an ; Wang, Licheng ; Lu, Change

Prostate cancer (PCa) is one of the most prevalent malignancies among men worldwide and remains the second leading cause of cancer-related mortality in this population. While androgen deprivation therapy (ADT) is initially effective, most patients eventually progress to castration-resistant prostate cancer (CRPC), a stage characterized by aggressive disease behavior and limited treatment options. Prostate-specific membrane antigen (PSMA) has emerged as a pivotal biomarker in PCa pathogenesis, with its overexpression in malignant cells providing a compelling target for both diagnostic imaging and therapeutic intervention.This review explores the multifaceted role of PSMA in tumor progression, highlighting its involvement in neoangiogenesis, metabolic reprogramming, and therapeutic vulnerabilities. We critically examine the latest advancements in PSMA-targeted treatment strategies, including radioligand therapy (e.g., ¹⁷⁷Lu-PSMA-617), antibody-drug conjugates, bispecific T-cell engagers, and small-molecule PSMA inhibitors. Clinical studies have demonstrated that PSMA-directed therapies can significantly reduce prostate-specific antigen (PSA) levels, improve radiographic progression-free survival (rPFS), and enhance patient-reported quality of life. However, challenges such as heterogeneous PSMA expression and acquired resistance necessitate further investigation. Ongoing clinical trials are actively exploring combinatory approaches, integrating PSMA-targeted therapy with radiotherapy, chemotherapy, and immunotherapy to optimize therapeutic efficacy. This review underscores the promise of PSMA-targeted strategies in advancing precision medicine for mCRPC, paving the way for improved survival outcomes and a better quality of life for affected patients.

01 Sep 2025·CURRENT OPINION IN UROLOGY

VISION, TheraP, LuTectomy and beyond – is there a role for lutetium therapy in biochemical recurrence?

Review

Author: Weindler, Jasmin ; Eapen, Renu S. ; Perera, Marlon L. ; Murphy, Declan G. ; Hennes, David ; Babst, Christa

Purpose of review:

This review synthesizes current evidence and recommendations for the use of lutetium-177 prostate-specific membrane antigen (LuPSMA) radioligand therapy across the spectrum of prostate cancer, focusing on its established use in metastatic castration-resistant prostate cancer (mCRPC), and evolving role in metastatic hormone-sensitive disease (mHSPC) and in neoadjuvant treatment of high-risk localized disease. We explore the potential for its use in biochemical recurrence (BCR) highlighting its limitations, and areas for future research.

Recent findings:

LuPSMA has demonstrated oncological efficacy and tolerability over standard of care treatments in mCRPC, supported by landmark trials such as VISION, TheraP, and PSMAfore. In mHSPC, the UpFront PSMA and PSMAddition trials have demonstrated promising improvements in undetectable PSA rates and progression-free survival when LuPSMA was combined with standard therapies. Furthermore, the LuTectomy trial has shown that neoadjuvant LuPSMA prior to radical prostatectomy in high risk localised prostate cancer can deliver high but variable doses of targeted radiation to PSMA expressing cells, and is surgically safe and tolerated well.

Summary:

LuPSMA radioligand therapy is a form of targeted therapy that has been shown to improve outcomes and quality of life in advanced disease with limited toxicity. While its use is well established in mCRPC, ongoing trials are exploring its efficacy in earlier disease stages and in combination with other therapies. Continued research and guideline development are essential to optimize LuPSMA's application across the prostate cancer disease spectrum, particularly in the BCR setting.

01 Sep 2025·SEMINARS IN NUCLEAR MEDICINE

PSMA-Targeted Positron Emission Tomography Imaging in Solid Tumors Other Than Prostate Carcinoma: An Update

Review

Author: Nyakale, Nozipho ; Li, Shaobo ; de Wiele, Christophe Van ; Maes, Alex ; Maes, Justine ; Sathekge, Mike

Prostate-specific membrane antigen (PSMA) has been previously shown to be over-expressed on newly formed vessels of a wide variety of solid tumors other than prostate carcinoma. Accordingly, the potential role of PSMA-targeted positron emitting tomography for staging, restaging and prediction of response to PSMA-targeted treatment modalities, including ¹⁷⁷Lu-PSMA-617, in other solid tumor types is being explored. Results derived from currently available studies on the role of PSMA-targeted imaging in solid tumors other than prostate carcinoma are encouraging with amongst others evidence of improved diagnostic accuracy in patients suffering from clear cell renal cell carcinoma and adenoid cystic adenocarcinoma of the salivary gland when compared to standard of care imaging, leading to a change in patient management in a significant number of patients. Furthermore, in hepatocellular carcinoma and glioblastoma, the comparable diagnostic accuracy of PSMA-targeted PET imaging when compared to contrast-enhanced CT and MRI suggest a potential use of PSMA-targeted PET when findings derived from morphological imaging are doubtful. Also, high PSMA-targeted PET-ligand uptake has been identified in iodine refractory thyroid carcinoma lesions as well as in triple negative breast carcinoma, suggesting a potential role for PSMA-targeted therapy in these patient populations. Thus far published results warrant, however, confirmation by larger prospective studies additionally assessing the longitudinal impact on patient outcomes.

402

News (Medical) associated with Lutetium (177 Lu) Vipivotide Tetraxetan

07 Aug 2025

·www.prnewswire.com

Aktis Oncology Appoints Accomplished Life Sciences Industry Veteran Mike Sherman to its Board of Directors

Life sciences executive brings over 30 years of leadership experience in oncology drug development and strategic transactions as Aktis continues to advance its proprietary pipeline of miniprotein radioconjugates BOSTON, Aug. 7, 2025 /PRNewswire/ -- Aktis Oncology, Inc., a clinical-stage oncology company focused on unlocking the breakthrough potential of targeted radiopharmaceuticals for patient populations not addressed by existing platform technologies, today announced the appointment of Mike Sherman as an independent director to its Board of Directors. "We are delighted to welcome Mike to the Aktis Board of Directors," said Matthew Roden, PhD, President and Chief Executive Officer of Aktis Oncology. "Mike brings exceptional experience leading successful oncology companies through critical development milestones and strategic transactions. His impressive track record of value creation and deep understanding of the oncology landscape will be invaluable as we advance our innovative radiopharmaceutical platform, including the NECTINIUM-2 Phase Ib clinical trial evaluating AKY-1189 for the treatment of patients with locally advanced or metastatic urothelial carcinoma, triple negative breast cancer, and other Nectin-4 expressing tumors." Mr. Sherman brings over 30 years of experience in the life sciences industry to Aktis' Board of Directors, with a distinguished track record of leadership as Chief Executive Officer and Board Director across multiple public and private companies. He currently serves as an independent Board Director at Werewolf Therapeutics and Tolremo Therapeutics, which are both focused on the advancement of novel cancer therapeutics. Most recently, he served as Chairman at Chimerix, overseeing the company's $935 million acquisition by Jazz Pharmaceuticals in 2025, and prior to that, served as Chimerix's Chief Executive Officer and Board Director. Prior to Chimerix, he served as President and Chief Executive Officer of Endocyte Inc., guiding the company from a $200 million market capitalization to its $2.1 billion acquisition by Novartis in 2018 for worldwide rights to PLUVICTO®, which was developed by Endocyte and is now a leading FDA-approved radiopharmaceutical treatment for advanced prostate cancer. Earlier, Mr. Sherman also served as Endocyte's Chief Financial Officer, playing a pivotal role in the company's initial public offering and subsequent financings. Mr. Sherman holds a BA in Economics from DePauw University and an MBA from the Tuck School of Business at Dartmouth. "I am excited to join the Aktis' Board of Directors at such a pivotal time as the company is establishing itself as a leader in the field of radiopharmaceuticals," said Mr. Sherman. "Aktis' vision and proprietary miniprotein radioconjugate technology opens up new opportunities to create treatment options for patients facing difficult-to-treat cancers. The company has made terrific progress with its pipeline and with the Eli Lilly discovery collaboration, and I look forward to working with the exceptional team to advance these promising therapies to patients." About Aktis Oncology Aktis Oncology, Inc. is a clinical-stage oncology company focused on unlocking the breakthrough potential of targeted radiopharmaceuticals for large patient populations not addressed by existing platform technologies. Aktis' most advanced pipeline program targets Nectin-4, a tumor-associated antigen found in urothelial and other solid cancers. Founded and incubated by MPM BioImpact, Aktis has developed its proprietary miniprotein radioconjugate platform to generate tumor targeting agents with properties ideal for alpha radiopharmaceuticals. Designed to maximize tumor killing through high penetration followed by internalization and retention in cancer cells, Aktis' miniprotein radioconjugates are designed to quickly clear from normal organs and tissues, thereby maximizing anticancer activity while minimizing side effects of treatment. The Aktis platform is isotope-agnostic and further enables clinicians to visualize and verify target engagement with imaging isotopes prior to exposure to therapeutic radioisotopes. Aktis also has a strategic collaboration with Eli Lilly and Company to leverage its miniprotein platform to develop novel radioconjugates outside of Aktis' proprietary pipeline. To learn more about Aktis Oncology, visit . Media Contact: Sean Leous ICR Healthcare (646) 866-4012 [email protected] Investor Contact: Peter Vozzo ICR Healthcare (443) 213-0505 [email protected] SOURCE Aktis Oncology WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

Phase 1Executive ChangeAcquisition

29 Jul 2025

·www.einpresswire.com

TD2 Oncology and Curadh Enter Strategic Collaboration to Advance Radiopharmaceutical Clinical Trials

Partnership brings together deep clinical expertise and novel radiopharmaceutical innovation to accelerate treatments for patients with aggressive solid tumors SCOTTSDALE, AZ, UNITED STATES, July 29, 2025 / EINPresswire.com / -- TD2 Oncology (TD2), a global, full-service oncology contract research organization (CRO) with extensive experience in complex oncology clinical trials, has entered a strategic collaboration with Curadh MTR, Inc. (Curadh), a biotechnology company pioneering molecularly targeted radiopharmaceutical therapies (MTRs) for solid tumors. The partnership combines TD2’s proven oncology execution capabilities with Curadh’s deep scientific innovation in the radiopharmaceutical space, accelerating the development of next-generation targeted therapies for patients with difficult-to-treat cancers. Radiopharmaceuticals deliver radiation directly to cancer cells, offering transformative potential across multiple tumor types. However, clinical development in this space remains complex, requiring specialized logistics, isotope handling, and navigating multi-jurisdictional regulations. As the global radiopharmaceuticals market approaches USD 7.51 billion and continues to grow, TD2 and Curadh will jointly address these challenges using an integrated clinical development model that spans regulatory strategy through early-phase execution. “This collaboration marks the beginning of a powerful partnership between two organizations dedicated to advancing precision oncology,” said Steve Gately, PhD, Chief Executive Officer of TD2. As radiopharmaceuticals continue to emerge as a powerful modality in cancer care, we’re proud to contribute our clinical trial execution capabilities to accelerate these promising therapies and help expand access to patients globally.” “TD2’s proven track record in complete oncology trials makes them the ideal partner as we bring our radiopharmaceutical programs into clinical development. This collaboration strengthens our abilities to navigate the unique challenges of MTR trials and positions us to deliver meaningful innovations for patients who urgently need new treatment options,” said Glenn Kazo, Chief Executive Officer of Curadh. The TD2–Curadh collaboration reflects a shared commitment to tackling some of the most complex challenges in oncology drug development. By combining operational strength and scientific innovation, both organizations aim to accelerate the delivery of radiopharmaceutical therapies that could redefine treatment paradigms for patients with difficult-to-treat cancers. Additional updates on program milestones and trial progress are expected in the coming months. About TD2 Oncology TD2 is a full-service global oncology contract research organization (CRO) CRO with deep expertise in complex oncology trials across a broad range of drug classes, including radiopharmaceuticals. Founded by Dr Dan Von Hoff in 2003, TD2 is dedicated to advancing oncology drug development with exceptional scientific insight, operational efficiency, and strategic execution. Leveraging decades of specialized experience, TD2 offers strategic, tailored solutions to accelerate the path from scientific discoveries to life-changing patient therapies. For more information, visit: www.td2inc.com . About Curadh MTR About Curadh: Curadh MTR, Inc., is dedicated to advancing second-generation radiopharmaceuticals through innovative drug design and strategic partnerships combining novel targets and new radioisotopes. Founded by Dr. Alison Armour, who led the clinical development of PSMA617 for Endocyte, later approved as Pluvicto ® , the world's leading radiopharmaceutical drug, Curadh is headed by an expert team in MTR development. For more information, visit: www.curadhmtr.com . Tara Franks TD2 Oncology tfranks@td2inc.com Visit us on social media: LinkedIn Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Radiation TherapyClinical Study

29 Jul 2025

·endpoints.news

Artbio attracts $132M as its alpha radioligand program moves into the clinic

The money is flowing this month for radiopharmaceutical companies with a presence in Europe. The latest to snag a major funding round is Artbio, which uncorked a $132 million Series B on Tuesday to move its alpha radioligand candidate for metastatic castration-resistant prostate cancer into trials. The 60-employee biotech has set up shop in the US, Switzerland, Norway and the UK. Artbio’s round follows a $99 million Series B for Nuclidium and a $75.5 million Series A for Actithera , which operated as a one-man shop during a laborious fundraising process. Both European startups announced their fundraises earlier this month. As the radiopharma space continues to mature, biotech startups and legacy drugmakers alike are betting on different isotopes to tackle cancer. “The area is still relatively in its infancy. Sometimes we want to think that it’s much more established thanks to Pluvicto, which continues to make great progress, and with Lutathera,” Artbio CEO Emanuele Ostuni said, referring to Novartis’ drugs. “But there’s still a lot more that has to come in terms of multiple payloads, multiple carrier molecules.” He compared it to the bustling antibody-drug conjugate field, but said he hopes the radioligand space will “play out a bit faster.” Artbio’s scientific co-founders are well-established in the alpha radio field. Øyvind Bruland and Roy Larsen invented Xofigo, the alpha radiopharmaceutical marketed by Bayer for prostate cancer. Artbio secured its funds from new investors Sofinnova Investments and B Capital, as well as existing backers F-Prime Capital, Omega Funds and Third Rock Ventures. Sofinnova general partner Maha Katabi will join Artbio’s board. She was on the board of radiopharma startup RayzeBio when it sold to Bristol Myers Squibb for $4.1 billion in 2023. RayzeBio focused on actinium, but Artbio is developing a suite of programs around the isotope Pb-212. The company has a steady supply of thorium-228, which it turns into a pure form of Pb-212. Artbio has forged multiple supply and manufacturing agreements over the past few years to solidify its presence and prepare for clinical trials. “We see the thorium-228 supply chain actually expanding quite meaningfully in the long term, so we’re not overly concerned about source material,” Ostuni said. “So far, we’ve not had any issue accessing what we need for everything, as well as for all of our planned activities, which we’ve already factored into our supply agreements.” In a press release, Katabi referred to Artbio’s generator technology as a “game-changer for navigating around supply and production challenges for radioisotopes in today’s complex environment.” Pharma giants that have bought up radiopharma startups in recent years have poured big dollars into supply deals and manufacturing. This includes companies like Bristol Myers, Eli Lilly and Novartis. A Phase 1/2 of Artbio’s first candidate, AB001, is “very imminent,” Ostuni said, with plans to run the trial in Europe and the US. It has also conducted a tech transfer with AlphaGen Therapeutics so the Shanghai-based biotech can run trials of AB001 in China, Ostuni said. Artbio’s reach is now quite extensive, with AB001 being manufactured across three continents. Expansion to a fourth continent will soon be revealed, though the CEO declined to disclose more details. “We want to be able to show that the supply chain actually applies to multi-center, multi-continent, multi-state [operations], as opposed to just doing everything in one city and shipping across town,” Ostuni said. “That’s a way to run a trial, of course, but we want to be able to have a supply chain that is scalable — that can modify to multiple programs and multiple indications. “Some may say we’re making life harder for ourselves by doing it this way,” Ostuni continued, “but we think it’s what we need to see in order to convince ourselves that this has a future.” The biotech also has plans to put a peptide program for solid tumors into human trials. It in-licensed that program from 3B Pharmaceuticals last November. Meanwhile, in earlier-stage development, Artbio also has a partnership with Parabilis Medicines (formerly FogPharma). A third internal program will also move toward the clinic, Ostuni said.

100 Deals associated with Lutetium (177 Lu) Vipivotide Tetraxetan

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Metastatic castration-resistant prostate cancer	Canada	Advanced Accelerator Applications USA, Inc.	25 Aug 2022
PSMA-Positive Castration-Resistant Prostatic Cancer	United States	Novartis Pharmaceuticals Corp.	23 Mar 2022

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Metastatic Prostate Carcinoma	Phase 3	France	Novartis AG	12 Sep 2024
Oligometastatic Prostate Carcinoma	Phase 3	United States	Novartis Pharmaceuticals Corp.	12 Mar 2024
Oligometastatic Prostate Carcinoma	Phase 3	China	Novartis Pharmaceuticals Corp.	12 Mar 2024
Oligometastatic Prostate Carcinoma	Phase 3	Japan	Novartis Pharmaceuticals Corp.	12 Mar 2024
Oligometastatic Prostate Carcinoma	Phase 3	Argentina	Novartis Pharmaceuticals Corp.	12 Mar 2024
Oligometastatic Prostate Carcinoma	Phase 3	Australia	Novartis Pharmaceuticals Corp.	12 Mar 2024
Oligometastatic Prostate Carcinoma	Phase 3	Austria	Novartis Pharmaceuticals Corp.	12 Mar 2024
Oligometastatic Prostate Carcinoma	Phase 3	Belgium	Novartis Pharmaceuticals Corp.	12 Mar 2024
Oligometastatic Prostate Carcinoma	Phase 3	Brazil	Novartis Pharmaceuticals Corp.	12 Mar 2024
Oligometastatic Prostate Carcinoma	Phase 3	Canada	Novartis Pharmaceuticals Corp.	12 Mar 2024

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05114746 (Pubmed \| Ann Nucl Med)	Phase 2	PSMA-Positive Castration-Resistant Prostatic Cancer PSMA-positive	35	[177Lu]Lu-PSMA-617	owmofoghjj(ozotsdlamy) = izqrxmqpmz rtbbcecnnu (ogstcqhcgk ) View more	-	10 Jul 2025
				[68Ga]Ga-PSMA-11	owmofoghjj(ozotsdlamy) = dndmavzyom rtbbcecnnu (ogstcqhcgk ) View more
NCT04443062 (BULLSEYE trial, ASCO2025)	Phase 2	Castration-sensitive prostate cancer PSMA-expressing	58	Lutetium-177-PSMA-617	jgsvbavcoa(cnyudeialm) = jedecfktag vnywgvonxr (xafkrlscqv ) View more	Positive	30 May 2025
				Lutetium-177-PSMA-617 (Standard of Care (SoC) - Deferred ADT)	jgsvbavcoa(cnyudeialm) = pwgtsjgmkg vnywgvonxr (xafkrlscqv ) View more
TriNetX database (ASCO2025)	Not Applicable	Metastatic castration-resistant prostate cancer Third line PSA50	-	177Lu-vipivotide tetraxetan PSMA	kadyptdbwy(xnffpfrhjk) = significantly lower rates with 177Lu-PSMA yzmepupdkx (lasiikocfw ) View more	Positive	30 May 2025
				Cabazitaxel
VISION and EAP (ASCO2025)	Not Applicable	Metastatic castration-resistant prostate cancer prostate specific membrane antigen	51	Lutetium-177 vipivotide tetraxetan	sslrxsnsha(jkryntgnfa) = kmfbbxzjkl gfulaurblf (sadxplymge, 9.4 - 25)	Negative	30 May 2025
EKNZ 2021-01271 (ASCO2025)	Not Applicable	Metastatic castration-resistant prostate cancer	333	177Lu-PSMA-I&T	cjrwvzkslk(ujmubstqky) = 14% adptfzwmvx (wfutmdszpa ) View more	Positive	30 May 2025
ASCO2025	Not Applicable	Metastatic castration-resistant prostate cancer PSMA expression	214	Enzalutamide	aubmuxmxgh(sayqdhztqg) = kairvixhvn qijpibhrld (dfkakdjzsc ) View more	Positive	30 May 2025
				Abiraterone Acetate	aubmuxmxgh(sayqdhztqg) = whuqmquyax qijpibhrld (dfkakdjzsc ) View more
NCT05150236 (EVOLUTION; ANZUP2001, ASCO2025)	Phase 2	Metastatic castration-resistant prostate cancer PSMA-positive	93	LuPSMA alone	xmyolyobkr(pugughycpi) = There were 2 deaths during LuPSMA+ICI treatment: myocarditis (treatment related) and sepsis (not treatment related) ffynfcvlkr (hfhokbmdkd ) View more	Positive	30 May 2025
				LuPSMA+ICI (ipilimumab and nivolumab)
NCT06216249 (FLEX-MRT, ASCO2025)	Phase 2	Metastatic castration-resistant prostate cancer PSMA positron emission tomography (PET)	90	Flexible dosing schedule of 177Lu-PSMA-617 RPT up to 12 cycles	ryuyemzsxq(qjioassdru) = ztwuvtdahb irabnilfcq (otxmxwwyol )	Positive	30 May 2025
				Fixed dosing schedule of 177Lu-PSMA-617 RPT 6 cycles	ryuyemzsxq(qjioassdru) = qqabhrmzzg irabnilfcq (otxmxwwyol )
NCT03805594 (CTgov)	Phase 1	Castration-Resistant Prostatic Cancer \| Metastatic castration-resistant prostate cancer \| Advanced Prostate Carcinoma ... View more	43	Lutetium Lu 177-PSMA-617+Pembrolizumab (Part A: Dosing Schedule 1 (Lutetium Lu 177-PSMA-617, Pembrolizumab))	xcjelzdphs = kpxfcqquww wdmmrpxfjt (pmfvbyownd, bqulsrsxpl - huvpdyunaf) View more	-	25 Feb 2025
				Lutetium Lu 177-PSMA-617+Pembrolizumab (Part A: Dosing Schedule 2 (Lutetium Lu 177-PSMA-617, Pembrolizumab))	xcjelzdphs = fslikkyzcc wdmmrpxfjt (pmfvbyownd, ehucunivza - vldrrkrhmz) View more
ASCO_GU2025 Manual	Not Applicable	Metastatic castration-resistant prostate cancer	643	177Lu-PSMA-617	ppejthgvir(komlpbmtnc) = xjrwtljoxj djbiijxgvq (vapwnixmbd, 14.6 - 16.3) View more	Negative	13 Feb 2025

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

AI Agents Built for Biopharma Breakthroughs

Accelerate discovery. Empower decisions. Transform outcomes.

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Lutetium (177 Lu) Vipivotide Tetraxetan

Overview

Basic Info

Structure/Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Biosimilar

Regulation